Hilary Shmeeda

Title: Hilary Shmeeda: Innovator in Liposomal Drug Delivery

Introduction

Hilary Shmeeda is a prominent inventor based in Givat Zeev, Israel. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of liposomal drug delivery systems. With a total of 8 patents to his name, Shmeeda's work has the potential to enhance the efficacy of cancer treatments.

Latest Patents

Among his latest patents, Shmeeda has developed a liposome composition comprising a liposomal prodrug of mitomycin C and a method of manufacture. This innovative composition features a lipophilic prodrug of mitomycin C that boasts an improved pharmacokinetic profile. The method for preparing this composition utilizes a solvent system made up of ethanol and tertiary butanol mixed in an adequate ratio. In one embodiment, the liposome composition consists of a population of lipid nanoparticles, which includes a first fraction of spherical liposomes and a second fraction of rod-shaped lipid nanoparticles, where the latter constitutes less than about 15% of the total population.

Another notable patent involves a liposome composition that co-encapsulates doxorubicin and a prodrug of mitomycin C. This composition features liposomes with a lipid layer that defines an internal aqueous compartment, where an anthracycline drug is entrapped in the internal aqueous phase, and the mitomycin C prodrug is incorporated into the lipid layer.

Career Highlights

Shmeeda has worked with several esteemed organizations throughout his career. Notably, he has been associated with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. and Lipomedix Pharmaceuticals Ltd. His work in these companies has allowed him to push the boundaries of drug delivery systems and improve therapeutic outcomes.

Collaborations

Throughout his career, Shmeeda has collaborated with notable figures in the field, including Yechezkel Barenholz and Alberto Gabizon. These collaborations have further enriched his research and development efforts.

Conclusion

Hilary Shmeeda's innovative work in liposomal drug delivery systems has the potential to significantly impact cancer treatment methodologies. His contributions through various patents and collaborations highlight his dedication to advancing pharmaceutical sciences.